BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Pick Your Favored kind of sandwich - 223 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- 3Civil rights leader Jesse Jackson hospitalized, family requests prayers
- 4How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- 5Former ‘Dancing with the Stars’ Pro Survives Plane Crash at LaGuardia That Left 2 Pilots Dead
- Giude to Best Web based Learning Stage
- How did birds survive while dinosaurs went extinct?
- Manual for 10 Scrumptious Specialty Mixed drinks
- Mom finds out she has cancer after noticing something was off while breastfeeding
- Well known Worldwide Caf\u00e9s to Experience
- Parents speak out as 4-year-old fights button battery injury in intensive care unit
- The Best Internet based Courses for Expertise Improvement
- Zelensky sees win for Ukraine as EU finally reaches funding deal
- Interoceanic Train derails in southern Mexico, injuring at least 15 and halting traffic on line
